A photo of Peter de Blank.

Peter de Blank, MD, MSCE

  • Co-Medical Director, Brain Tumor Center
  • Associate Professor, UC Department of Pediatrics

About

Biography

Dr. de Blank graduated from the University of California, San Francisco School of Medicine with a concentration in Medical Education. He completed his residency in Pediatrics, and fellowships in Pediatric Hematology & Oncology and Pediatric Neuro-Oncology at the Children’s Hospital of Philadelphia. He completed a Masters of Science in Clinical Epidemiology and Biostatistics at the University of Pennsylvania during his fellowship training. After completing his training, he became a faculty member at University Hospitals Rainbow Babies & Children’s Hospital in Cleveland in 2012. In 2017, Dr. de Blank joined the faculty at Cincinnati Children’s Hospital Medical Center as a member of the Pediatric Neuro-Oncology program.

Dr. de Blank’s clinical and research interests include children with central nervous system tumors, neurofibromatosis type 1 (NF1), and NF1-related tumors. His research focuses on the investigation of tissue microstructure in pediatric brain tumors through non-invasive imaging techniques such as MR relaxometry and diffusion tensor imaging. The goal of his research is to develop early radiographic tumor biomarkers to characterize pediatric brain tumors and predict their functional consequences. Tumor imaging research may guide early intervention efforts and direct support for children with brain tumors in order to improve clinical outcomes in children with brain tumors.

Dr. de Blank has been elected by peers for inclusion in the Best Doctors in America List.

BA: Stanford University, Stanford, CA, 1997.

BS: Chemistry, Stanford University, Stanford, CA, 1997.

MA: Stanford University, Stanford, CA, 1997.

MD: Emphasis in Medical Education, University of California, San Francisco School of Medicine, San Francisco, CA, 2005.

MS: Clinical Epidemiology, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 2011.

Intern: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2005-2006.

Resident: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2006-2008.

Fellow: Pediatric Hematology and Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2008-2011; Pediatric Neuro-Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2011-2012.

Interests

Pediatric neuro-oncology; neurofibromatosis type 1 (NF1); NF1-associated brain tumors

Services and Specialties

Cancer and Blood Diseases, Brain Tumor, Rasopathy, Neurofibromatosis

Interests

Cancer imaging; diffusion tensor imaging; MR relaxometry; magnetic resonance fingerprinting; developmental therapeutics

Research Areas

Cancer and Blood Diseases, Oncology

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. Lazow, MA; Nievelstein, MT; Lane, A; Bandopadhayhay, P; DeWire-Schottmiller, M; Fouladi, M; Glod, JW; Greiner, RJ; Hoffman, LM; Hummel, TR; et al. Neuro-Oncology. 2022.

Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1. Kotch, C; Avery, R; Getz, KD; Bouffet, E; de Blank, P; Listernick, R; Gutmann, DH; Bornhorst, M; Campen, C; Liu, GT; et al. Neuro-Oncology. 2022.

Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. DeWire, M; Lazow, M; Campagne, O; Leach, J; Fuller, C; Senthil Kumar, S; Stanek, J; de Blank, P; Hummel, TR; Pillay-Smiley, N; et al. Neuro-Oncology Advances. 2022; 4.

NIMG-08. A MULTI-CENTER RADIOMICS-BASED MODEL TO DIFFERENTIATE BETWEEN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS. Ly, I; Liu, T; Cai, W; Kwon, D; Michaels, O; Bredella, M; Jordan, J; Dombi, E; Widemann, B; Hirbe, A; et al. Neuro-Oncology. 2021; 23:vi128-vi129.

INNV-04. A MULTI-INSTITUTIONAL CLINICAL AND MRI REPOSITORY OF NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PERIPHERAL NERVE SHEATH TUMORS. Ly, I; Hirbe, A; Jordan, J; Michaels, O; Kwon, D; Borcherding, D; Srihari, D; Dombi, E; Widemann, B; Pollard, K; et al. Neuro-Oncology. 2021; 23:vi105-vi106.

CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS. Gardner, S; Koschmann, C; Tarapore, R; Allen, J; Zaky, W; Odia, Y; Hall, M; Daghistani, D; Khatib, Z; Aguilera, D; et al. Neuro-Oncology. 2021; 23:vi67-vi67.

Recommendations for Measurement of Attention Outcomes in Preschoolers With Neurofibromatosis. Klein-Tasman, BP; Lee, K; Thompson, HL; Janusz, J; Payne, JM; Pardej, S; de Blank, P; Kennedy, T; Janke, KM; Castillo, AD; et al. Neurology. 2021; 97:S81-S90.

Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1. Janusz, JA; Klein-Tasman, BP; Payne, JM; Wolters, PL; Thompson, HL; Martin, S; de Blank, P; Ullrich, N; Del Castillo, A; Hussey, M; et al. Neurology. 2021; 97:S73-S80.

Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor. Lazow, MA; Lawson, SA; Salloum, R; Hummel, TR; Pillay Smiley, N; Dewire-Schottmiller, MD; Fouladi, M; De Blank, P. Journal of Pediatric Hematology/Oncology. 2021; 43:e550-e553.

Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers. DeWire, M; Erker, C; Hummel, TR; Chow, LM L; de Blank, P; Salloum, R; Pillay-Smiley, N; Hoffman, L; Gilger, E; Gallagher, M; et al. Journal of Neuro-Oncology. 2021; 152:107-114.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey